MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will ...

Ansa Biotechnologies Inc., the trusted partner for DNA synthesis, today announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Mr. Hamilton will report ...

In a wide-ranging discussion on the future of genomics and cancer diagnostics in India, senior leaders from Strand Life ...

Xu, W. , Xing, X. and Cheng, S. (2025) Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer. International ...

The NBDL represents a transition from observing nature as something external to something that is molecularly intimate.

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...